$Aquestive(AQST)$
还需要时间审评。还有1.2亿美金。
未来就是裁员整合。
AQST disclosed receipt of an FDA letter identifying deficiencies that currently preclude labeling discussions for Anaphylm, while confirming the NDA review remains ongoing with no final regulatory decision made; the company continues to advance regulatory filings in Canada, Europe, and the UK, and ended 2025 with approximately $120M in cash to support operations.肾上腺素舌下膜